Non-small cell lung cancer nonsquamous · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Pemetrexed Variant #01 | — | R 13 666 | 21d | ~5.0 mo | ~13.4 mo | ~7 | ~R 95 222 PFS proxy · indirect | 14 |
Cisplatin and Vinorelbine (CVb) Variant #01 | — | R 3 333 | 21d | — | ~10.0 mo | ~7 | ~R 13 269 PFS proxy · indirect | 10 |
Tegafur and uracil monotherapy Partial | — | — | — | — | — | — | — | — |
UFT monotherapy Variant #04 Partial | — | — | 28d | — | — | 52 | — | 1 |
4 of 4 regimens shown